We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Effectiveness of PegInterferon and Ribavirin in Korean Patients With Chronic Hepatitis C

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01596517
First Posted: May 11, 2012
Last Update Posted: May 15, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Samsung Medical Center
Severance Hospital
Gangnam Severance Hospital
Seoul St. Mary's Hospital
Korea University Guro Hospital
Information provided by (Responsible Party):
Young-Suk Lim, Asan Medical Center
  Purpose
The purpose of this study is to investigate the efficacy and effectiveness of peginterferon alfa-2a and ribavirin therapy in Korean chronic hepatitis C patients.

Condition Intervention Phase
Chronic Hepatitis C Drug: Peginterferon alfa-2a plus ribavirin for HCV genotype 1 Drug: Peginterferon alfa-2a plus ribavirin for HCV genotype 2/3 Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Efficacy and Effectiveness of Combination Therapy With Pegylated Interferon Alfa-2a and Ribavirin in Korean Patients With Chronic Hepatitis C

Resource links provided by NLM:


Further study details as provided by Young-Suk Lim, Asan Medical Center:

Primary Outcome Measures:
  • The proportion of patients achieving sustained virological response (SVR) [ Time Frame: at 24 weeks after cessation of treatment ]
    SVR is defined as a documented undetectable serum HCV RNA by PCR at 24 weeks after cessation of treatment


Secondary Outcome Measures:
  • The proportion of patients achieving early virological response (EVR) [ Time Frame: at 12 weeks of treatment ]
    EVR is defined as reduction of HCV RNA level by 2 log or more at 12 weeks of treatment

  • the proportion of patients achieving complete EVR (cEVR) [ Time Frame: at 12 weeks of treatment ]
    cEVR is defined as HCV RNA undetectable by PCR at 12 weeks of treatment

  • The proportion of patients achieving end-of-treatment response (ETR) [ Time Frame: at week 48 for HCV genotype 1 and at week 24 for HCV genotype 2/3 ]
    ETR is defined as HCV RNA undetectable at the end of treatment.


Enrollment: 272
Study Start Date: June 2003
Study Completion Date: May 2012
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Korean CHC
Two CHC patient groups. One is CHC patients who are treated with combination of peginterferon alfa-2a and ribavirin in a prospective, multicenter, industry-sponsored, open-label, uncontrolled, community-based clinical trial (Pegasys Expanded Access Program) conducted at 6 tertiary referral centers in Korea between 2003 and 2004. Another is a cohort of hepatitis C patients who were treated in a single tertiary referral hospital (Asan Medical Center, Seoul, Korea) between 2004 and 2008.
Drug: Peginterferon alfa-2a plus ribavirin for HCV genotype 1
Patients with genotype 1: treatment with peginterferon α-2a (Roche, Basel, Switzerland) 180 μg/week and daily ribavirin dose of 1,000 mg (for patients with body weight <75kg) or 1,200 mg (for patients with body weight ≥75kg) for 48 weeks.
Other Names:
  • Pegasys
  • Copegus
Drug: Peginterferon alfa-2a plus ribavirin for HCV genotype 2/3
Patients with genotype 2 or 3: treatment with peginterferon α-2a 180 μg/week and daily ribavirin dose of 800 mg for 24 weeks.
Other Names:
  • Pegasys
  • Copegus

Detailed Description:
A retrospective analysis of a prospective, multicenter, industry-sponsored, open-label, uncontrolled, community-based clinical trial of combination of peginterferon alfa-2a and ribavirin (Pegasys Expanded Access Program) conducted at 6 tertiary referral centers in Korea between 2003 and 2004 and a cohort of hepatitis C patients who were treated in a single tertiary referral hospital (Asan Medical Center, Seoul, Korea) between 2004 and 2008
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria: all of below

  • adults aged 18-70 years
  • serum anti-HCV antibody (+)
  • HCV RNA detectable by PCR
  • compensated liver disease (Child-Pugh class A)

Exclusion Criteria: any of below

  • HCV genotype other than 1, 2, or 3
  • acute hepatitis C
  • decompensated cirrhosis or hepatocellular carcinoma
  • other liver disease such as hepatitis A or B, or autoimmune hepatitis
  • HIV Ab(+)
  • severe depression or other psychiatric disease
  • previous organ transplantation
  • absolute neutrophil count (ANC) < 1,000 cells/mm3 or platelet count < 75,000 cells/mm3, or hemoglobin (Hb) < 13 g/dL for men, <12 g/dL for women
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01596517


Locations
Korea, Republic of
Asan Medical Center
Seoul, Korea, Republic of, 138-736
Sponsors and Collaborators
Asan Medical Center
Samsung Medical Center
Severance Hospital
Gangnam Severance Hospital
Seoul St. Mary's Hospital
Korea University Guro Hospital
Investigators
Principal Investigator: Young-Suk Lim, M.D., Ph.D. Asan Medical Center
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Young-Suk Lim, Professor, Asan Medical Center
ClinicalTrials.gov Identifier: NCT01596517     History of Changes
Other Study ID Numbers: AMC2003-0059
First Submitted: May 7, 2012
First Posted: May 11, 2012
Last Update Posted: May 15, 2012
Last Verified: May 2012

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis C
Hepatitis, Chronic
Hepatitis C, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Ribavirin
Peginterferon alfa-2a
Interferon-alpha
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents
Immunologic Factors
Physiological Effects of Drugs